Aetna modified CPB 1053 for lovotibeglogene autotemcel (Lyfgenia), effective January 5, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its Lyfgenia coverage policy under CPB 1053 Aetna system, governing a one-time gene therapy for sickle cell disease. The primary billing code is HCPCS J3394 (injection, lovotibeglogene autotemcel, per treatment), with supporting CPT codes 81370–81383 for HLA typing and CPT 96365–96368 and 96413–96415 for infusion administration. If your practice or facility treats adolescent and adult sickle cell patients, this update sets the exact criteria Aetna will use to approve or deny reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Lovotibeglogene Autotemcel (Lyfgenia) |
| Policy Code | CPB 1053 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Bone Marrow Transplant, Pediatric/Adult Hematology |
| Key Action | Contact National Medical Excellence (NME) at 877-212-8811 for precertification before administering Lyfgenia at an Aetna GCIT-designated facility |
Aetna Lyfgenia Coverage Criteria and Medical Necessity Requirements 2026
Aetna's Lyfgenia coverage policy under CPB 1053 sets a narrow, high-bar path to approval. This is a one-time gene therapy — one dose, one approval, no second chances at this particular treatment. Get the documentation right before you submit.
Prior authorization is mandatory. Every Aetna participating provider must get precertification through National Medical Excellence (NME) at 877-212-8811. This is not a standard PA queue. NME handles gene therapy requests under Aetna's GCIT program, which means dedicated review. Don't route this through a standard prior auth channel and expect it to move.
Beyond prior auth, Lyfgenia must be administered at an Aetna Institutes® GCIT-designated facility — unless the member's specific plan has opted out of that requirement. Verify site-of-care designation before scheduling the treatment. Administering at a non-designated site is a fast path to a claim denial with no easy appeal.
Medical necessity criteria require ALL of the following to be met:
| # | Covered Indication |
|---|---|
| 1 | Member is 12 years of age or older |
| 2 | Confirmed sickle cell disease with one of these genotypes via molecular or genetic testing: βs/βs, βs/β0, or βs/β+ |
| 3 | Documented history of at least two severe vaso-occlusive episodes per year over the previous two years |
| 4 | Eligible for hematopoietic stem cell transplant (HSCT) but unable to find a matched 10/10 HLA-related donor (CPT codes 81370–81383 support the HLA typing documentation) |
| 5 | No prior HSCT |
| 6 | No prior Lyfgenia or any other gene therapy |
| 7 | No more than two α-globin gene deletions |
| 8 | Has experienced, at any time in the past, an inadequate response or intolerance to hydroxyurea (HCPCS S0176), OR a documented contraindication to hydroxyurea |
The hydroxyurea step is worth flagging. Aetna requires evidence that the member tried and failed hydroxyurea — or has a documented reason they can't take it. If that trial history isn't in the chart, document it now. Missing this single criterion will stop your claim cold.
The prescriber must be a hematologist or a physician consulting with one. This is a specialty-specific requirement, not a suggestion.
Aetna Lyfgenia Exclusions and Non-Covered Indications
Aetna considers all uses of Lyfgenia outside the criteria above experimental, investigational, or unproven. Full stop. There is no off-label pathway here.
Beyond the indication restrictions, the coverage policy lists a set of absolute exclusions. If a member has any of the following, Lyfgenia is not covered:
| # | Excluded Procedure |
|---|---|
| 1 | HIV-1 or HIV-2, active hepatitis B (ICD-10 B16.x, B18.0, B18.1, B19.10, B19.11), or hepatitis C (B17.10, B17.11, B18.2, B19.20, B19.21) |
| 2 | Any prior or current malignancy (ICD-10 C00.0–C96.Z) |
| 3 | Clinically significant active infection (ICD-10 range A00.0–B99.9) |
| 4 | Advanced liver disease — bridging fibrosis, cirrhosis, or active hepatitis |
| 5 | Uncorrected bleeding disorder (ICD-10 D65–D69.9) |
| 6 | Immunodeficiency disorder (ICD-10 D80.x, D81.x) |
| 7 | Severe cerebral vasculopathy |
| 8 | Clinically significant pulmonary hypertension |
| 9 | Inadequate pulmonary or cardiac function |
| 10 | Uncontrolled seizure disorder |
| 11 | Renal impairment with creatinine clearance below 70 mL/min/1.73 m² |
This exclusion list is long and specific. The real issue here is that many sickle cell patients have comorbidities that could disqualify them. Screen for these before you initiate the precertification process. Finding a disqualifying condition after NME review wastes time and creates a denial record that can complicate future appeals.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Sickle cell disease (βs/βs, βs/β0, βs/β+), age ≥12, ≥2 VOEs/year, no matched HLA donor, hydroxyurea failure/contraindication, no prior HSCT or gene therapy | Covered (one dose) | J3394, D57.0–D57.9 | Precertification via NME required; GCIT-designated facility required |
| Sickle cell disease with active HIV, HBV, or HCV | Not Covered | B16.x–B19.x, B20, B97.35 | Absolute exclusion |
| Sickle cell disease with prior or current malignancy | Not Covered | C00.0–C96.Z | Absolute exclusion |
| Sickle cell disease with uncorrected bleeding disorder | Not Covered | D65–D69.9 | Absolute exclusion |
| Sickle cell disease with immunodeficiency | Not Covered | D80.x–D81.x | Absolute exclusion |
| Any off-label use of Lyfgenia | Experimental / Not Covered | — | Considered investigational by Aetna |
| Second or repeat dose of Lyfgenia | Not Covered | J3394 | Policy covers one dose total; prior gene therapy is an exclusion |
| Lyfgenia at non-GCIT facility (unless plan exclusion applies) | Not Covered | — | Site-of-care requirement; verify before scheduling |
Aetna Lyfgenia Billing Guidelines and Action Items 2026
This policy was effective January 5, 2026. If you're billing or preparing to bill for Lyfgenia, here are the steps your team needs to take now.
| # | Action Item |
|---|---|
| 1 | Contact NME before scheduling. Call 877-212-8811 to start the precertification process. Do not schedule the infusion until you have authorization in hand. Lyfgenia is a gene therapy with significant reimbursement exposure — a denied claim at that dollar amount is not recoverable in most practices. |
| 2 | Confirm GCIT site-of-care status. Check the Aetna Institutes® GCIT Designated Networks list before the procedure date. If your facility isn't on that list, you need to refer the patient to a designated center or confirm that the member's plan has waived the requirement. Document that verification in the record. |
| 3 | Build a complete medical necessity packet before submitting. You need molecular/genetic testing confirming the genotype (βs/βs, βs/β0, or βs/β+), two years of documented severe vaso-occlusive episodes, HLA typing results showing no matched 10/10 donor (support this with CPT 81370–81383), proof of hydroxyurea trial failure or contraindication using HCPCS S0176 records, and confirmation that no prior HSCT or gene therapy was performed. |
| 4 | Screen for exclusions before initiating the PA. Run the member against the full exclusion list — HIV status, hepatitis serology, malignancy history, renal function (creatinine clearance), pulmonary and cardiac assessments, seizure history. A disqualifying finding after NME review delays care and creates administrative burden with no upside. |
| 5 | Bill J3394 for the drug itself, and use the correct infusion codes. HCPCS J3394 is the billing code for lovotibeglogene autotemcel. The administration should be billed with CPT 96365–96368 for standard IV infusion or CPT 96413–96415 if chemotherapy administration codes are more appropriate given your payer's Lyfgenia billing guidelines. Confirm with your coding team which set fits your facility's workflow and Aetna's reimbursement structure. |
| 6 | Ensure the prescriber on the claim is a hematologist. Aetna requires a hematologist to prescribe or co-sign. If the ordering physician doesn't meet that specialty requirement, the claim will deny. Check the NPI taxonomy on your claim before submission. |
| 7 | If you're uncertain about any of these criteria for a specific patient, loop in your compliance officer before the effective date passes without a clear plan. Lyfgenia billing is high-stakes, low-volume, and highly scrutinized. One misaligned claim can trigger a broader audit of your gene therapy billing practices. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Lyfgenia Under CPB 1053
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J3394 | HCPCS | Injection, lovotibeglogene autotemcel, per treatment |
Other HCPCS Code Related to the Policy
| Code | Type | Description |
|---|---|---|
| S0176 | HCPCS | Hydroxyurea, oral, 500 mg |
Supporting CPT Codes Related to the Policy
| Code | Type | Description |
|---|---|---|
| 81370 | CPT | Human leukocyte antigen (HLA) Class |
| 81371 | CPT | Human leukocyte antigen (HLA) Class |
| 81372 | CPT | Human leukocyte antigen (HLA) Class |
| 81373 | CPT | Human leukocyte antigen (HLA) Class |
| 81374 | CPT | Human leukocyte antigen (HLA) Class |
| 81375 | CPT | Human leukocyte antigen (HLA) Class |
| 81376 | CPT | Human leukocyte antigen (HLA) Class |
| 81377 | CPT | Human leukocyte antigen (HLA) Class |
| 81378 | CPT | Human leukocyte antigen (HLA) Class |
| 81379 | CPT | Human leukocyte antigen (HLA) Class |
| 81380 | CPT | Human leukocyte antigen (HLA) Class |
| 81381 | CPT | Human leukocyte antigen (HLA) Class |
| 81382 | CPT | Human leukocyte antigen (HLA) Class |
| 81383 | CPT | Human leukocyte antigen (HLA) Class |
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96366 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96367 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96368 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique |
Key ICD-10-CM Diagnosis Codes
Covered Primary Diagnoses:
| Code | Description |
|---|---|
| D57.0 | Sickle-cell disorders |
| D57.1 | Sickle-cell disorders |
| D57.2 | Sickle-cell disorders |
| D57.3 | Sickle-cell disorders |
| D57.4 | Sickle-cell disorders |
| D57.5 | Sickle-cell disorders |
| D57.6 | Sickle-cell disorders |
| D57.7 | Sickle-cell disorders |
| D57.8 | Sickle-cell disorders |
| D57.9 | Sickle-cell disorders |
Exclusionary Diagnoses (claim will deny if present):
| Code | Description |
|---|---|
| B16.0–B16.9 | Acute hepatitis B (multiple codes) |
| B17.0 | Acute delta-(super) infection of hepatitis B carrier |
| B17.10, B17.11 | Acute hepatitis C |
| B18.0 | Chronic viral hepatitis B with delta-agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| B18.2 | Chronic viral hepatitis C |
| B19.10, B19.11 | Unspecified viral hepatitis B |
| B19.20, B19.21 | Unspecified viral hepatitis C |
| B20 | Human immunodeficiency virus [HIV] disease |
| B97.35 | HIV-2 as cause of diseases classified elsewhere |
| C00.0–C96.Z | Current malignancy (full range) |
| D47.1 | Chronic myeloproliferative disease |
| D47.2 | Monoclonal gammopathy |
| D47.3 | Essential (hemorrhagic) thrombocythemia |
| D47.4 | Osteomyelofibrosis |
| D65–D69.9 | Coagulation defects, purpura, and other hemorrhagic conditions (uncorrected bleeding disorder) |
| D80.0–D80.9 | Immunodeficiency with predominantly antibody defects |
| D81.0–D81.x (see full policy) | Combined immunodeficiencies (additional codes apply per the full CPB 1053 policy) |
| A00.0–B99.9 | Certain infectious and parasitic diseases (clinically significant active infection — broad range) |
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.